Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported upbeat fourth-quarter earnings.The company posted adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consensus of $10.71. The company reported sales of $3.88 billion, up 3% year over year, beating the consensus of $3.79 billion.Regeneron expects fiscal 2026 GAAP gross margin of 79%–80%, with adjusted gross margin of 83%–84%. The company forecasts adjusted R&D expenses of $5.9–$6.1 billion in 2026, and non-GAAP SG&A expen ...